Hemerion team has been developing its technology since 2010 within the frame of scientific and clinical research teams located in Lille. Our endeavours led to a successful clinical validation in 2021.

January 2014

Proof of concept

Proof of concept
A first preclinical study proves the effectiveness of Hemerion therapeutics approach on glioblastoma (GBM) human cell lines. The experiments associated a photoactivatable drug and an innovative photonic system.
January 2015

New preclinical study confirms therapy effects

Medical imaging

A new study allows to optimize the photonic illumination scheme and enhance the therapy effects.

January 2016

Optimizing laser light delivery

The photonic therapy is further improved with a light power regimen study that leads to better tolerance.

May 2017

Kick-off of phase I clinical trial: INDYGO

For the first time, our technology combining a photosensitizing drug and an innovative photonic device is delivered upfront, during the surgery of patients newly diagnosed with glioblastoma. 
Indygo is a Phase I study sponsored by the University Hospital of Lille.
CHU Lille Logo
July 2017

Awarded by world’s largest medical laser society

M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.

March 2018

Entrepreneurship program with Eurasanté

The Hemerion’s founders enter the Eurasanté entrepreneurship program, an incubator dedicated to health start-up companies

Logo Eurasanté

June 2018

Patients enrollment successfully completed

The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with  Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.

September 2018

Hemerion technology introduced in Nature

The clinical world premiere is highlighted in Nature’s 2018 September issue. An article detailing the clinical trial INDYGO and the technology being developed to treat glioblastomas is published in a special issue of journal (

October 2018

European Neurosurgery Congress

European Neurosurgery Congress

The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.

June 2019

Introduction of the Hemerion technology in the USA

Introduction of the Hemerion technology in the USA

The Hemerion technology is demonstrated by Pr. N. Reyns at an international neurosurgery meeting in Cambridge – Boston (MA, USA) and in New-York (NY, USA) during Fluorescence-Guided Surgery Brain Tumor Symposiums hosted at The Icahn School of Medicine at Mount Sinai by Pr. C. G. Hadjipanayis.

December 2019

University of Lille Foundation awards Hemerion Therapeutics

The University of Lille’s Foundation awards the Hemerion Therapeutics founders for their scientific and entrepreuneurship involvement establishing a healthtech company.

Logo Fondation Université de Lille

July 2020

I-Lab innovation competition

Hemerion is awarded during I-Lab innovation competition and granted to upgrade its lead product and better meet neurosurgeons needs.
September 2020

Establishment of Hemerion Therapeutics


Hemerion Therapeutics is founded by the scientists and inventors of the technology, among them M. Vermandel, C. Dupont, N. Reyns, S. Mordon and M. Andraud gather deep scientific how-know and entrepreneurship skills to lead the company. In the mean time, Hemerion is awarded the French Tech Label that recognizes high potential start-up companies.

Logo La French Tech

October 2020

Hemerion joins Neighborhood

Hemerion joins the Voisin Consulting Neighborhood program, a life science innovation center that offers tailored mentoring, coaching and global access to health tech entrepreneurs.Neigborhood logo
January 2021

Hemerion gathers 1.5M€ in funding

Hemerion Technology
For its preliminary funding round, Hemerion gathers 1.5M€ in dilutive and non-dilutive funding to further validate its therapeutic approach.
January 2021

FDA grants Hemerion Orphan Drug designation

In the USA, the Hemerion’s technology becomes granted Orphan Drug Designation by the FDA.

June 2021

Preliminary results published in Journal of Neuro-Oncology

Ground breaking preliminary results from the clinical study are published in the Journal of Neuro-Oncology. The Hemerion’s technology covered the 2018’s May issue.

September 2021

Phase II study granted authorization in Europe

Authorization granted for a phase 2 clinical trial that aims to evaluate the technology developed by Hemerion. This study sponsored by Lille University Hopital (France) is multicentric with additional investigative center in Brussels (Erasme Hospital – Belgium).